Deals, Insiders, R&D

The high-roller club in biopharma: Who’s paying top-dollar for upfronts? And who are the busiest players at the deal table?

Nothing says “I love this” in biopharma quite like a big upfront deal payment.

In an era when biobucks are handed around in a somewhat carefree fashion, it’s the cash down payments that tell you where the leaders in this industry are seeing the next big advances coming from.

We asked Chris Dokomajilar, who launched DealForma, to crunch the numbers for us on upfronts and deal totals for the industry dating back to the start of 2017, and a few things stand out in the results.

First and foremost, dealmaking in an era of sky-high biotech valuations means going in big when you believe there’s a game changing new leap in pharma tech on the table. That’s what Merck and Bristol-Myers Squibb proved, along with the rest of the top 5, where totals leaned heavily on a single transaction.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 37,800+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->